Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function.
Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function.
复制标题
中等剂量的 hGH（0.64 mg/d）可以改善 GH 缺乏但基线心功能正常的成年人的血脂，但不能改善心血管功能。
DOI：
--
复制
发表时间：
2011
影响因子：
5.8
通讯作者：
D. Kleinberg
中科院分区：
文献类型：
--
作者：
C. Newman;Katalin A Frisch;B. Rosenzweig;R. Roubenoff;M. Rey;Teresa Kidder;Yuan Kong;A. Pursnani;S. Sedlis;A. Schwartzbard;D. Kleinberg
上下文
关于低剂量GH对GH缺乏（GHD）成人心肺功能影响的数据有限。
目标
目的是评估低剂量GH对GHD成人运动能力和超声心动图参数的影响。
设计
该研究是一项为期6个月的双盲、安慰剂对照随机试验。
设置
本研究在综合临床研究中心进行。
参与者
研究了30名患有GHD的低血糖成年人。
干预
受试者随机接受重组人GH或安慰剂治疗6个月，随后接受开放标签重组人GH治疗12个月。
主要观察指标
主要终点为运动持续时间、最大耗氧量和左心室射血分数。次要终点是收缩和舒张功能的超声心动图指数、左心室质量、脂质和身体成分。
结果
在6个月双盲期，平均GH剂量为0.64 mg/d。平均IGF-I sd评分从-4.5增加至-1.0。运动持续时间、最大耗氧量、左心室射血分数和其他超声心动图参数在基线时正常，没有变化。GH使总胆固醇和低密度脂蛋白胆固醇降低7.5%（P = 0.016）和14.7%（P = 0.002）（与安慰剂相比P = 0.04）。平均瘦体重增加2.2 kg（P = 0.004），脂肪量减少1.7 kg（P = 0.21），体脂百分比减少2.5%（P = 0.018），但组间变化不显著。
结论
人生长激素没有改善运动能力或超声心动图参数或减少脂肪量，但显着降低总胆固醇和低密度脂蛋白胆固醇，增加IGF-I，并增加瘦体重。这些结果表明，对人GH的反应是可变的，应在基线和治疗期间进行评估。
CONTEXT
Data regarding effects of lower-dose GH on cardiopulmonary function in GH-deficient (GHD) adults are limited.
OBJECTIVES
The objective was to assess effects of lower-dose GH on exercise capacity and echocardiographic parameters in GHD adults.
DESIGN
The study was a 6-month double-blind, placebo-controlled randomized trial.
SETTING
The study was conducted at the General Clinical Research Center.
PARTICIPANTS
Thirty hypopituitary adults with GHD were studied.
INTERVENTION
Subjects were randomized to recombinant human GH or placebo for 6 months, followed by open-label recombinant human GH for 12 months.
MAIN OUTCOME MEASURES
Primary endpoints were exercise duration, maximal oxygen consumption, and left ventricular ejection fraction. Secondary endpoints were echocardiographic indices of systolic and diastolic function, left ventricular mass, lipids, and body composition.
RESULTS
In the 6-month double-blind phase, mean GH dose was 0.64 mg/d. Mean IGF-I sd score increased from -4.5 to -1.0. Exercise duration, maximal oxygen consumption, left ventricular ejection fraction, and other echocardiographic parameters were normal at baseline and did not change. GH decreased total and low-density lipoprotein cholesterol by 7.5% (P = 0.016) and 14.7% (P = 0.002) (P = 0.04 vs. placebo). Mean lean body mass increased by 2.2 kg (P = 0.004), fat mass decreased by 1.7 kg (P = 0.21), and percent body fat decreased by 2.5% (P = 0.018), although between-group changes were not significant.
CONCLUSIONS
Human GH did not improve exercise performance or echocardiographic parameters or decrease fat mass but significantly decreased total and low-density lipoprotein cholesterol, increased IGF-I, and increased lean body mass. These results indicate that responses to human GH are variable and should be assessed at baseline and during treatment.